Nivolumab-Induced Hemophilia A Presenting as Gastric Ulcer Bleeding in a Patient With NSCLC.
暂无分享,去创建一个
M. Kudo | I. Matsumura | T. Okuno | K. Nakagawa | H. Hayashi | H. Ueda | H. Kawakami | Takahiro Kumode | R. Kato | Keigo Sano | K. Handa
[1] M. Suarez‐Almazor,et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Matthew D. Hellmann,et al. Immune‐Related Adverse Events Associated with Immune Checkpoint Blockade , 2018, The New England journal of medicine.
[3] C. Leissinger,et al. Acquired hemophilia A: Updated review of evidence and treatment guidance , 2017, American journal of hematology.
[4] N. Lazaridis,et al. Acquired Hemophilia and Anti-Hu Paraneoplastic Neurologic Syndrome in Small Cell Lung Cancer. , 2017, The American journal of the medical sciences.
[5] J. McQuade,et al. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy , 2017, Journal of Immunotherapy for Cancer.
[6] S. Nair,et al. Immunotherapy-Associated Hemolytic Anemia with Pure Red-Cell Aplasia. , 2016, The New England journal of medicine.
[7] C. Mateus,et al. Hemophilia A induced by ipilimumab. , 2011, The New England journal of medicine.
[8] T. Gajewski,et al. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma , 2009, Cancer Immunology, Immunotherapy.
[9] N. Saijo,et al. Acquired factor VIII inhibitor in a patient with adenocarcinoma of the lung. , 1992, Japanese journal of clinical oncology.